IntelliCyt and Tekon Biotech Announce China Distribution Agreement

Share Article

IntelliCyt expands product sales to life science and pharmaceutical markets in China.

IntelliCyt Corporation, a provider of cell and bead-based screening solutions for phenotypic drug discovery, antibody discovery and in-vitro toxicity testing, today announced an exclusive agreement with Tekon Biotech to distribute their products in the Chinese life science arena. Tekon will feature IntelliCyt’s new iQue™ Screener at the SLAS China conference, June 6-7 in Shanghai.

“Tekon is a leading distributor of world-class scientific products in China with over 25 years of experience in the life science systems and tools market,” commented Terry Dunlay, CEO at IntelliCyt. “We are excited about expanding our cell and bead-based screening solutions business into China, and the powerful potential this partnership has to reach new pharma, biotech, and life science customers for continued growth of our product line.”

“We are seeing increased need for both cell and bead-based screening flexibility in the Chinese life science market,” said David Hadfield, CEO of Tekon Biotech. “The capability of IntelliCyt platforms to screen large libraries and evaluate compound effects on primary immune system cells and other cells in solution rapidly and in a cost efficient manner is key to addressing this need.”

About Tekon Biotech

Tekon Biotech, founded in 1988, sells and supports a broad range of technologies to the China life sciences market. Tekon’s customers include all the major pharmaceutical and biotech companies plus the top 50 universities. Tekon is headquartered in Shanghai with offices in Hong Kong and Taipei. Tekon Biotech takes pride in providing the best service and technical support. For more information, visit

About IntelliCyt Corporation

IntelliCyt Corporation develops innovative, high-throughput, high-content cell and bead-based screening solutions for use in phenotypic drug discovery, antibody discovery and in vitro toxicity testing. IntelliCyt’s proprietary technologies, instrumentation, assays and software products address the pervasive need to provide turnkey solutions that increase productivity in pharmaceutical, biotechnology, and life science research. For more information, please visit

Share article on social media or email:

View article via:

Pdf Print

Contact Author

R. Terry Dunlay, President and CEO
Visit website